Novo Nordisk receives approval for Victoza® in China

Novo Nordisk announced today that the Chinese State Food and Drug Administration (SFDA) has approved Victoza® for the treatment of type 2 diabetes. Further information: Media: Investors: Mike Rulis Klaus Bülow Davidsen Tel: (+45) 4442 3573 Tel: (+45) 4442 3176 [email protected] [email protected] Jannick Lindegaard Tel: (+45) 4442 4765 [email protected] In North America: In North America: Ken Inchausti Hans Rommer Tel: (+1) 609 786 8316 Tel: (+1) 609 919 7937 [email protected] [email protected] Company Announcement no 16 2011

The release as fetched from its publisher. novonordisk.com ↗